Recent Updates — GNMSF
Genmab announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab, an investigational bispecific antibody, in combination with pembrolizumab versus pembrolizumab alone. Based on a first interim analysis by an independent data monitoring committee, the treatment met both primary endpoints of overall survival and objective response rate in patients with first-line PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma. The combination reduced the risk of death by 50% (HR 0.50) and demonstrated a statistically significant improvement in objective response rate (odds ratio 3.17). The safety profile was generally well tolerated with no new signals identified. Genmab plans to engage global regulatory authorities and submit full results for presentation at a future medical meeting. Genmab is an international biotechnology company dedicated to developing innovative antibody medicines for cancer.
Genmab A/S increased its share capital by 24,592 shares following the exercise of employee warrants. The company raised approximately DKK 37.9 million in proceeds through cash subscriptions at prices ranging from DKK 1,334.50 to DKK 1,615.00 per share. This transaction represents roughly 0.04% of total share capital and was executed without preemption rights for existing shareholders. Genmab is an international biotechnology company dedicated to developing innovative antibody medicines for cancer and other serious diseases.
Genmab A/S reported first-half 2026 revenue of $2,051 million, a 25% increase from the prior year period. Royalty revenue rose to $1,708 million, driven by higher DARZALEX and Kesimpta sales, while EPKINLY net product sales reached $312 million. The company announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma. Genmab updated its full-year 2026 guidance, raising the revenue midpoint to $4,425 million and adjusted operating profit midpoint to $1,225 million due to stronger royalty and product sales expectations. The firm operates in the biotechnology industry, developing and commercializing antibody-based therapies for cancer and autoimmune diseases.